Benefits of Resveratrol

Evidence-Based Benefits

• Inflammatory marker reduction — a 2019 meta-analysis (Koushki et al., 17 RCTs, n=736) found resveratrol significantly reduced CRP and TNF-alpha levels, particularly at doses ≥150mg/day for ≥8 weeks
• SIRT1 activation — resveratrol directly activates sirtuin 1, a NAD+-dependent deacetylase that suppresses NF-kB transcription and promotes anti-inflammatory gene expression
• Metabolic improvement — a 2019 meta-analysis (Mousavi et al., 28 RCTs) found resveratrol improved fasting glucose, insulin, HbA1c, and insulin resistance in type 2 diabetes patients
• COX-2 suppression — resveratrol inhibits COX-2 expression at the transcriptional level, reducing prostaglandin E2 production without affecting protective COX-1
• Endothelial function — clinical trials show resveratrol improves flow-mediated dilation and reduces arterial stiffness through enhanced nitric oxide bioavailability

What the Research Says

Resveratrol gained fame from the "French Paradox" hypothesis and has since been studied in over 200 clinical trials. A comprehensive meta-analysis by Koushki et al. (2019, 17 RCTs, n=736) confirmed significant reductions in CRP and TNF-alpha. For metabolic health, Mousavi et al. (2019, 28 RCTs) demonstrated improvements in glucose, insulin, and HbA1c in diabetic patients. The primary challenge is low oral bioavailability (~1-2%), with extensive first-pass metabolism converting resveratrol to glucuronide and sulfate conjugates. However, these metabolites may also have biological activity. Newer formulations (micronized, liposomal) aim to improve absorption. Resveratrol remains one of the most promising anti-inflammatory polyphenols with multi-target activity.

Related Conditions